A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis (IC) and Hunner's Lesions
Phase 1
Completed
- Conditions
- Chronic Interstitial Cystitis
- Interventions
- Drug: LiRIS® 400 mg
- First Posted Date
- 2013-06-18
- Last Posted Date
- 2015-12-18
- Lead Sponsor
- Allergan
- Target Recruit Count
- 10
- Registration Number
- NCT01879683
- Locations
- 🇺🇸
William Beaumont Hospital, Royal Oak, Michigan, United States
🇺🇸Advance Urology Institute, Daytona Beach, Florida, United States
NATRELLE® 410 X-Style and L-Style Breast Implants Continued Access Study
Not Applicable
Terminated
- Conditions
- Breast ReconstructionBreast Implant RevisionBreast Augmentation
- Interventions
- Device: Anatomically shaped, silicone-filled breast implants with low height/projection or extra-full projection
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2020-06-22
- Lead Sponsor
- Allergan
- Target Recruit Count
- 1951
- Registration Number
- NCT01870869
- Locations
- 🇺🇸
John Decorato, Staten Island, New York, United States
🇺🇸Raymond Isakov, Cleveland, Ohio, United States
🇺🇸Roy Hong, Palo Alto, California, United States
A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension
Phase 2
Completed
- Conditions
- GlaucomaOcular Hypertension
- Interventions
- Drug: Brimonidine Tartrate Ophthalmic Solution 0.2%Drug: Bimatoprost Ophthalmic Solution 0.01%Drug: Fixed-Combination Bimatoprost/BrimonidineDrug: Vehicle Ophthalmic Solution
- First Posted Date
- 2013-05-29
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Allergan
- Target Recruit Count
- 112
- Registration Number
- NCT01863953
An Observational Study of Dry Eye Prior to Laser-Assisted in Situ Keratomileusis (LASIK) Therapy
Completed
- Conditions
- Dry Eye Syndromes
- Interventions
- Other: No Treatment
- First Posted Date
- 2013-05-16
- Last Posted Date
- 2014-03-14
- Lead Sponsor
- Allergan
- Target Recruit Count
- 400
- Registration Number
- NCT01854905
NATRELLE® 410 Full and Moderate Height/Projection Breast Implant Continued Access Post-Approval Study
Not Applicable
Terminated
- Conditions
- Breast ReconstructionBreast Implant RevisionBreast Augmentation
- Interventions
- Device: Anatomically shaped silicone gel-filled breast implants
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2015-08-11
- Lead Sponsor
- Allergan
- Target Recruit Count
- 3811
- Registration Number
- NCT01853605
A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons
Completed
- Conditions
- Glaucoma, Primary Open AngleOcular Hypertension
- Interventions
- First Posted Date
- 2013-05-14
- Last Posted Date
- 2019-04-19
- Lead Sponsor
- Allergan
- Target Recruit Count
- 1830
- Registration Number
- NCT01853085
Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients
Phase 3
Completed
- Conditions
- Urinary Incontinence
- Interventions
- Biological: OnabotulinumtoxinA
- First Posted Date
- 2013-05-13
- Last Posted Date
- 2019-11-21
- Lead Sponsor
- Allergan
- Target Recruit Count
- 114
- Registration Number
- NCT01852045
- Locations
- 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Riley Hospital for Children, Indianapolis, Indiana, United States
A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity
Phase 3
Completed
- Conditions
- Urinary Incontinence
- Interventions
- Biological: OnabotulinumtoxinA
- First Posted Date
- 2013-05-13
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- Allergan
- Target Recruit Count
- 95
- Registration Number
- NCT01852058
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇧🇪UZ Antwerpen, Antwerpen, Belgium
JUVÉDERM VOLUMA® to Enhance the Appearance of the Asian Nose
Not Applicable
Completed
- Conditions
- Asian Nose Enhancement
- Interventions
- Device: Crosslinked hyaluronic acid gel
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Allergan
- Target Recruit Count
- 29
- Registration Number
- NCT01846039
A Study to Compare a New Eye Drop Formulation With Refresh Contacts®
Phase 3
Completed
- Conditions
- Contact Lens Lubrication
- Interventions
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Allergan
- Target Recruit Count
- 365
- Registration Number
- NCT01844388
© Copyright 2025. All Rights Reserved by MedPath